Abstract
The 5th CIHLMU Infectious Disease Symposium, Munich, Germany, March 12, 2016 brought together Tuberculosis Experts from developed and low middle-income countries to discuss the control of drug resistance Tuberculosis. The meeting featured 9 presentations: Tuberculosis history and current scenario, Tuberculosis and migration - current scenario in Germany, Mechanism of Tuberculosis resistance development, Epidemiology of resistance – transmission vs. new generation of resistance, The impact of diagnostic in patients beyond – sensitivity and specificity, The Bangladesh regimen – new hope trough old drugs, New drugs and regimens – an overview on studies and Multi and Extensively Drug Resistant Tuberculosis from Europe. The presentations were followed by a panel discussion.Serious Multidrug Resistance epidemic in some countries may jeopardize the progress in Tuberculosis control. In this meeting epidemiology, mechanism, immigration and screening, diagnosis, research and treatment of drug resistant tuberculosis were discussed.
Highlights
The Center for International Health – CIHLMU convened the 5th CIH Infectious Disease Symposium – Drug Resistant Tuberculosis “Old Disease – New Challenge” on the 12th of March 2016, in Munich, Germany (Fig. 1)
Summary of presentation Mycobacterium ulcerans existed since the Jurassic period (150 million years ago) [2], Mycobacterium tuberculosis (MTB) emerged about 3 million years ago [2] and was first described by Robert Koch in 1882
MTB is airborne transmitted by droplet and the main epidemiological important form is the pulmonary tuberculosis
Summary
The Center for International Health – CIHLMU convened the 5th CIH Infectious Disease Symposium – Drug Resistant Tuberculosis “Old Disease – New Challenge” on the 12th of March 2016, in Munich, Germany (Fig. 1). Tuberculosis (TB) is an old disease, but not a disease from the past, TB is still a public health challenge in many countries. In 2014, 9.6 million cases of TB were estimated worldwide, 3.3% of new cases and 20% of previously treated cases had Multidrug Resistant TB (MDR-TB) [1]. The aim of this symposium was to discuss holistically the drug resistant TB in developing and developed settings. Experts with diverse background and specialties were invited to discuss the epidemiology, etiology, Presentation summaries
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
